Compass Therapeutics Report issue

For profit Phase 1 Phase 3
Founded: Vancouver BC Canada (2013)
Status: Acquired by Zymeworks Inc. (2016)

Organization Overview

First Clinical Trial
2019
NCT03881488
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Compass Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (2)

ctx-009 (2 trials)

paclitaxel (taxol) (1 trial)

Drugs in Phase 1 Trials (2)

ctx-471 (1 trial)

ctx-8371 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasm Metastasis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4